Solopharm CEO Mamuka Mikhelashvili took part in an RBC St. Petersburg round table discussion titled «Product Quality: How It Is Evolving in Russia and Who Can Influence It». The event brought together industry leaders to explore how quality standards are transforming amid today’s challenging economic environment.
A key question on the agenda: is the market ready to sacrifice quality for affordability? Participants acknowledged that, across various sectors, rising costs and business pressures can create a temptation to cut corners on materials and production technologies.
In his speech, Mamuka Mikhelashvili emphasized that the pharmaceutical industry operates under fundamentally different rules. Stringent requirements from the Ministry of Health, Roszdravnadzor, and the Ministry of Industry and Trade establish a robust quality control system that leaves no room for compromise when it comes to patient safety and drug efficacy.
He also highlighted a critical nuance: even with identical active ingredients, medicines can differ significantly in quality. This depends on advanced production technologies, the purity of active substances, the presence or absence of preservatives, and the quality of excipients. These factors directly impact patient tolerance and the ultimate therapeutic outcome.
The discussion also touched on the dietary supplement segment, where regulatory oversight is less strict and quality variability is higher, requiring greater consumer awareness.
For Solopharm, participation in the RBC round table was an opportunity to reaffirm the company’s core philosophy: in pharmaceuticals, quality is not a variable — it is a constant commitment, immune to economic fluctuations.
Solopharm Press Office Comment
«We are convinced that in the pharmaceutical industry, quality is a foundation, not a competitive advantage. Patients and physicians must be able to trust a drug regardless of external factors. That is why we rigorously monitor the quality of our products, implement control at every stage of production, and believe it is essential to openly discuss these issues with the market».
